Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]

9月4日，第十七届中国生物产业大会在汉开幕。本届大会由中国生物工程学会等17家国家级学（协）会与中国科学报社共同主办，是 我国生物产业领域规模最大、影响最广的大型专业活动。 在光谷科技会展中心，大会集中展出了国内外生物产业基地、科研机构及龙头企业的最新成果，多项源自武汉、技术领先乃至"全球首 个"的重大创新产品集中亮相。 武汉禾元生物科技股份有限公司（以下简称"禾元生物"）展出了全球首创的植物源重组人血清白蛋白注射液奥福民®。一周多前，作 为全球首个"稻米造血"一类新药，该药品正式用于患者治疗，改写了人血清白蛋白依赖血浆提取的历史。 同济医院展示的光学脑机接口，在全球首创融合脑电图和近红外光谱多模态传感系统，主要用于脑出血康复，预计明年可上市。 中国生物产业大会现场。主办方供图 会上发布的《中国生物经济发展报告2025》显示，我国生物经济产业规模稳居全球第一，并呈现持续增长态势，在生物药在研品种、 脑机接口、高精度数字切片等前沿领域已实现"并跑"甚至"领跑"。 武汉自2018年起成为中国生物产业大会永久举办地之一。目前，武汉已形成覆盖创新研发、规模生产、临床运用全链条的生物医药产 业集群，产业规模突破5500 ...

Core Insights - The 17th China Bio-Industry Conference was held on September 4, 2025, in Wuhan, showcasing the latest innovations in the bio-manufacturing sector [1][3] - The conference highlighted the achievements of Wuhan's Optics Valley Bio-City, which has become a leading hub for biopharmaceuticals in China, housing over 4,200 companies and nurturing 531 high-tech enterprises [3][6] Group 1: Event Highlights - The conference released the "Most Innovative Bio-Manufacturing Base" list, recognizing ten national bio-industry bases, including Wuhan, Shanghai, Beijing, Hangzhou, and Shenzhen [1] - Five companies from Wuhan, including He Yuan Bio, Aibotai, and Youzhiyou, were ranked among the top 20 most innovative enterprises from hundreds of projects across 23 national bio-industry bases [1] Group 2: Achievements in Bio-Medicine - In the first half of the year, Optics Valley Bio-City approved 14 new class I innovative drugs for clinical trials, the highest number in three years, and 28 class III medical devices, matching last year's total [4] - The city is currently developing over 400 class I new drugs, accounting for 90% of the province's total, and has certified over 307 class III medical devices, representing 70% of the province's total [4] Group 3: Notable Exhibits - Major companies from Optics Valley Bio-City showcased groundbreaking products at the conference, including the world's first 5.0T whole-body MRI system and a novel "rice-derived" recombinant human albumin injection [4] - Binhui Bio's OH2 injection, the first oncolytic virus drug using type II herpes simplex virus as a carrier, is undergoing critical clinical research and has received national support for major new drug development [4]